

*file*

FORM PTO-1449 (Modified)		Attorney Docket No.: 20093A-002100US		Application No.: 09/301,380	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Gerald P. Murphy, <i>et al.</i>			
		Filing Date: June 15, 2001		Group: 1635	
Reference Designation		U.S. PATENT DOCUMENTS			
Page 1 of 1					
Examiner Initial	Document No.	Name	Class	Sub-class	Filing Date (If Appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>					
	Document No.	Date	Country	Class	Sub-class
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
<u>MWS</u> AA	Schwab, G. <i>et al.</i> , An Approach for New Anticancer Drugs: Oncogene-Targeted Antisense DNA, <i>Annals of Oncology</i> 5:55-58, 1994.				
<u>MWS</u> AB	Matveeva, O. <i>et al.</i> , A Rapid In Vitro Method For Obtaining RNA Accessibility Patterns For Complementary DNA Probes: Correlation With An Intracellular Pattern and Known RNA Structures, <i>Nucleic Acids Res.</i> 25:5010-6, 1997.				
<u>MWS</u> AC	Flanagan, Michael W., <i>Antisense Comes of Age</i> , <i>Cancer and Metastasis Reviews</i> 17:169-176, 1998.				
<u>MWS</u> AD	Ho, Siew Peng <i>et al.</i> , <i>Antisense Oligonucleotides for Target Validation in the CNS</i> , <i>Current Opinion in Molecular Therapeutics</i> 1:336-343, 1999.				
<u>MWS</u> AE	Holmlund, Jon T <i>et al.</i> , <i>Toward Antisense Oligonucleotide Therapy for Cancer: ISIS Compounds in Clinical Development</i> , <i>Current Opinion in Molecular Therapeutics</i> 1:372-385, 1999.				
AF					
AG					
AH					
AI					
AJ					
AK					
AL					
AM					
AN					
EXAMINER	<i>M Schimel</i>	DATE CONSIDERED		<i>8/25/02</i>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
5012889v1